Product Code: SR1623A162_Report
Market Overview:
The global metabolomics market size reached US$ 2.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.7 Billion by 2028, exhibiting a growth rate (CAGR) of 11.55% during 2023-2028.
Metabolomics refers to the large-scale study of metabolites, or small molecules, in cells, biofluids, tissues and organisms. It is an analytical approach for systematic metabolic profiling and fingerprinting in various biological samples and systems. It consists of various detection techniques, such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), along with separation techniques, such as gas chromatography. These techniques are commonly used for metabolome studies, toxicology testing and developing personalized medicine. They also provide an assessment of health and an insight into the causes and treatment of medical ailments, such as cardiovascular and neurological diseases and cancer.
The increasing prevalence of cancer and other chronic diseases is one of the key factors driving the growth of the market. Furthermore, a significant increase in the pharmaceutical industry, along with the rising demand for personalized medicines, is also providing a boost to the market growth. Metabolomics facilitates the study of genes and proteins, along with the development of biomarkers that aid in the discovery and development of medicines and managing disease progression. Additionally, the integration of metabolomics with machine learning (ML) is also favoring the market growth. ML aids in the accurate interpretation of data generated using the NMR and MS techniques and automates complex, repetitive and time-consuming processes. Advanced ML software also offers comprehensive analysis and visualization functions for the representation of large amounts of data. Other factors, including rapid urbanization and extensive research and development (R&D) activities in the field of biotechnology, are projected to drive the market in the upcoming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global metabolomics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, indication and application.
Breakup by Product:
- Metabolomics Instruments
- Metabolomics Bioinformatics Tools and Services
Breakup by Indication:
- Cancer
- Cardiovascular Disorders
- Neurological Disorders
- Inborn Errors of Metabolism
- Others
Breakup by Application:
- Biomarker and Drug Discovery
- Toxicology
- Nutrigenomics
- Personalized Medicine
- Others
Breakup by Region:
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Agilent Technologies Inc., Biocrates Life Sciences AG, Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Human Metabolome Technologies Inc., Metabolon Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc., Waters Corporation, etc.
Key Questions Answered in This Report:
- How has the global metabolomics market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What has been the impact of COVID-19 on the global metabolomics market?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the indication?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global metabolomics market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Metabolomics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Metabolomics Instruments
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Metabolomics Bioinformatics Tools and Services
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Indication
- 7.1 Cancer
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Cardiovascular Disorders
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Neurological Disorders
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Inborn Errors of Metabolism
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by Application
- 8.1 Biomarker and Drug Discovery
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Toxicology
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Nutrigenomics
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Personalized Medicine
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Agilent Technologies Inc.
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Biocrates Life Sciences AG
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.3 Bio-Rad Laboratories Inc.
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 Bruker Corporation
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.5 Danaher Corporation
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.6 Human Metabolome Technologies Inc.
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.7 Metabolon Inc.
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.8 Shimadzu Corporation
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.9 Thermo Fisher Scientific Inc.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.10 Waters Corporation
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.10.3 Financials
- 13.3.10.4 SWOT Analysis